All News
Filter News
Found 2,734 articles
-
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
11/9/2023
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter ended September 30, 2023.
-
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
11/9/2023
Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced the presentation of data from two HBV clinical trials at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023.
-
New Real-World Data Show TREMFYA® (guselkumab) Was Associated With Clinically Meaningful Improvements in Patient-Reported Outcomes for Adults Living With Active Psoriatic Arthritis
11/8/2023
Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, today announced new data from the CorEvitas Psoriatic Arthritis (PsA) and Spondyloarthritis Registry that showed a substantial proportion of people living with treatment-resistant active PsA and using TREMFYA® (guselkumab) in real-world settings reported meaningful improvements in pain, physical function and fatigue through six months.
-
Alpha Pro Tech, Ltd. Announces Third Quarter 2023 Financial Results
11/7/2023
Alpha Pro Tech, Ltd. announced financial results for the three and nine month period ended September 30, 2023.
-
Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors
11/6/2023
Adverum Biotechnologies, Inc. today announced the appointment of C. David Nicholson, Ph.D., as an independent member of its Board of Directors, effective November 3, 2023.
-
Aeglea BioTherapeutics Announces Grants of Inducement Awards - November 03, 2023
11/3/2023
Aeglea BioTherapeutics, Inc. announced that Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 729,600 shares of common stock of Aeglea to six non-executive employees as equity inducement awards under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan, as amended.
-
Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
11/2/2023
Legend Biotech Corporation today announced that two oral presentations and five poster presentations featuring new and updated data from the CARTITUDE clinical development program evaluating ciltacabtagene autoleucel (cilta-cel) will be presented at the 65th American Society of Hematology Annual Meeting and Exposition taking place in San Diego from December 9-12.
-
Altasciences Completes Expansion of New State-Of-The-Art Laboratory in Columbia, Missouri
10/31/2023
Altasciences is pleased to announce the completion of its laboratory facilities in Columbia, MO.
-
With recent high-profile failures, experts say safety concerns and a lack of diversification are hindering the field—but still hold out hope for an approval.
-
NovelMed Commences Phase II Trial for Anti-Bb Antibody (NM8074) in Treatment-Naïve PNH Patients: A Glimpse into the PNH Study Progress
10/30/2023
NovelMed Therapeutics is excited to announce the commencement of its Phase II clinical trial targeting treatment-naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) patients with its groundbreaking anti-Bb antibody, NM8074.
-
Ardelyx, Inc. Reports Employment Inducement Grants - October 30, 2023
10/30/2023
Ardelyx, Inc. announced between October 11, 2023 and October 29, 2023 the compensation committee of the company’s board of directors granted forty-seven new non-executive employees options to purchase an aggregate of 635,024 shares of the company’s common stock, and granted fifty-one new non-executive employees an aggregate of 591,900 Restricted Stock Units.
-
LEADING RESEARCH INSTITUTES TO PRESENT NEW DATA USING LUNAPHORE'S COMET™ TECHNOLOGY AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 38th ANNUAL MEETING
10/25/2023
Bio-Techne Corporation (NASDAQ: TECH) today announced that Lunaphore, a Bio-Techne brand, will have its technologies featured in several presentations by prominent research centers at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place in San Diego, November 1-5, 2023.
-
Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive NSCLC and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023
10/21/2023
Eli Lilly and Company announced results from both the LIBRETTO-431 Phase 3 study, which evaluated Retevmo® versus platinum-based chemotherapy.
-
Shockwave Medical Introduces Enhanced Coronary IVL Catheter in the United States
10/20/2023
Shockwave Medical, Inc. announced today the planned U.S. introduction of the Shockwave C 2+ Coronary Intravascular Lithotripsy (IVL) catheter following approval by the U.S. Food and Drug Administration.
-
Sequana Medical announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission
10/19/2023
Conference call with live webcast by Sequana Medical today at 03:00 pm CEST / 09:00 am EST
-
Elixirgen Therapeutics Announces Promising Phase 1/2 Data on EXG-5003, a Controllable Self-Replicating RNA (c-srRNA) Vaccine Against SARS-CoV-2
10/16/2023
Elixirgen Therapeutics, Inc. today announced promising data from a Phase 1/2 trial (NCT04863131) evaluating EXG-5003, a SARS-CoV-2 vaccine developed with the Company’s temperature controllable self-replicating RNA (c-srRNA) technology.
-
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyCF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial
10/16/2023
ContraFect Corporation (Nasdaq: CFRX) today announces that the U.S. Food and Drug Administration (FDA) has notified the company that it has completed the safety review of its Investigational New Drug (IND) application for CF-370 for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), and concluded that the company may proceed with its Phase 1 clinical study.
-
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
10/12/2023
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced initial clinical data for RLY-4008 (lirafugratinib) in patients with FGFR2-altered solid tumors.
-
Helsinn closes financing agreement with BancaStato to support business objectives and growth
10/10/2023
Helsinn Group announces the signing of a new financing agreement with BancaStato, effective from September 2023.
-
AstriVax Strengthens Leadership Team by Welcoming Chief Development Officer (CDO) Dr. Mathieu Peeters and Chief Financial Officer (CFO) Barbara Freitag
10/10/2023
AstriVax is pleased to announce that Dr. Mathieu Peeters and Barbara Freitag have joined the company’s leadership team as Chief Development Officer and Chief Financial Officer, respectively.